HilleVax, Inc. Banner Image

HilleVax, Inc.

  • Ticker HLVX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
HilleVax, Inc. Logo Image
  • 51-200 Employees
  • Based in Boston, Massachusetts
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 millionMore cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults.
HilleVax, Inc.

Most Recent Annual Report

HilleVax, Inc.
MOST RECENT 2022 Annual Report and Form 10K
HilleVax, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!